ANI PHARMACEUTICALS INC - 8-K Filing

ANI Pharmaceuticals released an updated investor presentation detailing its strategic transformation into a rare disease company and its proposed acquisition of Egetis Therapeutics. (Items: 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act)

SEC EDGAR ·

Tickers: $ANIP

Read the full article at SEC EDGAR

More Regulatory news